OncoMax to Present at International Oncology Conferences

OncoMax, Ltd. (“OncoMax”), a portfolio company of Russia-based Maxwell Biotech Venture Fund founded with the participation of Russian Venture Company announced today that it will be presenting the results of development of its lead product OM-RCA-01 at two major upcoming conferences on oncology.

27th Annual EAU Congress

Date — February 24–28, 2012
Venue — Le Palais des Congrès de Paris, Paris, France
Presentation: Does dose-dependent targeting of fibroblast growth factor (FGF) receptor 1 (FGFR1) impact on growth of renal cell carcinoma?
Presenter: Dr. Ilya V. Tsimafeyeu, Chief Scientific Adviser with OncoMax.

AACR Annual Meeting 2012

Date — April 1–4, 2012
Venue — McCormick Place, Chicago, IL, USA
Presentation: Preclinical activity of OM-RCA-01, a humanized anti-FGFR1 antibody, in renal cell carcinoma (RCC).
Presenter: Dr. Ilya V. Tsimafeyeu, Chief Scientific Adviser with OncoMax.

 

Анна Зеленкова,
PR директор, ООО «Максвелл Биотех Групп»;
Тел: +7 (495) 411-6992
E-mail: zelenkova@maxwellbiotech.ru